Analyst John Newman works at CANACCORD and is focused on the Healthcare sector with 230 price targets and ratings documented since 2014 spanning on 18 stocks. Analyst's average stock valuation to be materialised ratio is 28.35% with an average time for price targets to be met of 84.53 days.
Most recent stock forecast was given on REGN, Regeneron Pharmaceuticals, Inc at 16-Sep-2022.
John Newman best performing recommendations are on IMGN (IMMUNOGEN, INC).
The best stock recommendation documented was for AGIO (AGIOS PHARMACEUTICALS, INC) at 6/9/2016. The price target of $50 was fulfilled within 5 days with a profit of $6.22 (11.06%) receiving and performance score of 22.13.
Average potential price target upside